CellaVision AB (publ) (CLVSF) Stock

About CellaVision AB (publ)

CellaVision AB (publ), a company established in Lund, Sweden, in 1994, specializes in the development and distribution of digital analytical solutions for blood and body fluid samples. Their offerings cater to the healthcare services sector, with a significant global presence spanning Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company's product portfolio includes advanced hardware such as the CellaVision DM1200 and CellaVision DM9600, which are designed to automatically capture digital images from blood smears and various body fluid preparations, alongside the CellaVision DC-1 analyzer. Complementing their instrumentation is a suite of specialized software applications. For instance, the CellaVision Peripheral Blood Application streamlines and standardizes the morphological examination of peripheral blood smears for laboratory professionals. Similarly, the CellaVision Advanced RBC Application facilitates a comprehensive evaluation of red blood cell morphology, while the CellaVision Body Fluid Application offers automated and standardized analysis for body fluid preparations. To enhance collaboration and flexibility, the CellaVision Remote Review Software eliminates geographical barriers in the smear review process. Further enriching their ecosystem are tools such as the CellaVision Server Software, which unifies workflows across single or multiple testing sites, and the CellaVision Dashboard, providing instant insights into analyzer and reviewer performance metrics. For staff development, the cloud-based CellaVision Proficiency Software aids laboratory managers in assessing and enhancing team competency in cell morphology. Educational resources include CellaVision CellAtlas, combining mini-lectures with an extensive cell image database. Finally, CellaVision VET extends their digital microscopy solutions to the field of veterinary hematology. Their clientele primarily consists of hospital and commercial diagnostic laboratories.

CellaVision AB (publ) is headquartered in SE.

CellaVision AB (publ) (CLVSF) stock trades at $14.00 with a market capitalization of $333.92M. The stock is valued at a price-to-earnings (P/E) ratio of 27.39, price-to-book of 3.99, price-to-sales of 4.78. Over the past 52 weeks the stock has ranged between $13.49 and $19.28, and currently trades 27.4% below its 52-week high. It pays a dividend yielding 2.14%.

On profitability, CellaVision AB (publ) generates a return on equity (ROE) of 14.59%, above the typical market average, return on capital employed of 16.27%, an operating margin of 22.23%, a net profit margin of 17.46%.

Official website: www.cellavision.com